FIELD: pharmaceutical industry.
SUBSTANCE: invention provides composition containing 0.1-0.5% nicotinic acid, 0.01-0.05% olifen-containing preparation, 0.5-1 mln ME interferon, and solvent. Use of this composition allows interferon dose to be lowered in single time administration cases. Bioavailability and residence time in system bloodstream of preparation are increased. In addition, liver first passage effect is avoided as well as accompanying unfavorable reactions resulting in changed preparation structure. Preparation also alleviates inflammatory phenomena in focuses of primary virus contact with microorganism cells.
EFFECT: expanded therapeutical possibilities.
5 cl, 3 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTERFERON-CONTAINING COMPOSITION FOR THE TREATMENT OF CHRONIC DISEASES OF THE UPPER RESPIRATORY WAYS | 2022 |
|
RU2789513C1 |
| AGENT FOR TREATING GASTROINTESTINAL DISTURBANCES AND METHOD FOR MAKING THEREOF | 2008 |
|
RU2396968C2 |
| ANTI-RADIATION COMPOSITION BASED ON CHITINO-GLUCAN COMPLEX OF OYSTER MUSHROOMS | 2022 |
|
RU2804298C1 |
| DRUG FOR RESPIRATORY INFECTIOUS DISEASES GLUCAFERON | 2011 |
|
RU2450812C1 |
| PHARMACEUTICAL COMPOSITION AND METHOD FOR PULMONARY ADMINISTRATION THEREOF | 2010 |
|
RU2445119C2 |
| RAPAMYCIN-CONTAINING COMPOSITION ADMINISTERED BY INHALATION FOR TREATING AGE-RELATED DISEASES | 2015 |
|
RU2718583C2 |
| MEANS AND METHOD FOR PREVENTION OF INTERSTITIAL PNEUMONIA OF INFECTIOUS ETIOLOGY | 2021 |
|
RU2784177C1 |
| ANTI-VIRAL IMMUNOTROPIC AGENT FOR TREATMENT OF ARVI | 2018 |
|
RU2672888C1 |
| COMPOSITIONS FOR DRUG INTRODUCTION | 2009 |
|
RU2554814C2 |
| ZINC-CONTAINING AEROSOL COMPOSITION | 2009 |
|
RU2410082C1 |
